HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care
- PMID: 21307144
- DOI: 10.1158/1078-0432.CCR-10-1920
HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care
Abstract
Purpose: To analyze HER2 status in primary breast cancer (PBC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be predictive of change in HER2 expression.
Experimental design: HER2 was investigated by immunohistochemistry, silver in situ hybridization (SISH), and FISH, in a series of 137 tumors, building up a tissue microarray to concurrently analyze each single PBC and metastatic (MBC) on the same slide.
Results: HER2 status was discordant in 14 cases (10%): 12 negative in PBC and positive in metastases and two positive in PBC and negative in metastases (P = 0.04). These findings were confirmed by a PCR based test termed Multiplex Ligation-dependent Probe Amplification (MLPA). HER2 status changed in hormone receptor-positive BC more frequently than in negative ones (P = 0.002). In addition, we evaluated HER2 gene and chromosome 17 copy number by SISH in the 123 cases with unchanged HER2 status during progression. We found consistent HER2 gene copy number stability in the 100 nonamplified cases. Conversely, of the 23 amplified PBC, 13 (57%) demonstrated a significant increase in the HER2 gene and chromosome 17 copy number in their paired metastases (P = 0.01), as defined by SISH (k = 0.54, P < 0.0001) and MLPA. Patients who changed HER2 status from negative to positive, presented significant longer time to progression when treated with trastuzumab compared to those who were untreated (P = 0.04).
Conclusions: When feasible, HER2 reassessment in metastatic lesions should be carefully taken into account, especially for metastases coming from primary hormone receptor-positive BC.
Similar articles
-
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.Cancer. 2010 Nov 15;116(22):5168-78. doi: 10.1002/cncr.25430. Cancer. 2010. PMID: 20661914
-
Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.Cancer. 2005 May 1;103(9):1763-9. doi: 10.1002/cncr.20987. Cancer. 2005. PMID: 15786420
-
Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.J Clin Oncol. 2008 Oct 20;26(30):4869-74. doi: 10.1200/JCO.2007.13.4296. Epub 2008 Sep 15. J Clin Oncol. 2008. PMID: 18794552
-
[Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].Orv Hetil. 2001 Nov 18;142(46):2563-8. Orv Hetil. 2001. PMID: 11770175 Review. Hungarian.
-
HER2 testing in breast cancer: NCCN Task Force report and recommendations.J Natl Compr Canc Netw. 2006 Jul;4 Suppl 3:S1-22; quiz S23-4. J Natl Compr Canc Netw. 2006. PMID: 16813731 Review.
Cited by
-
Macrophages Promote Subtype Conversion and Endocrine Resistance in Breast Cancer.Cancers (Basel). 2024 Feb 5;16(3):678. doi: 10.3390/cancers16030678. Cancers (Basel). 2024. PMID: 38339428 Free PMC article.
-
The dynamics of HER2-low expression during breast cancer progression.Breast Cancer Res Treat. 2023 Oct;201(3):437-446. doi: 10.1007/s10549-023-07020-z. Epub 2023 Jul 12. Breast Cancer Res Treat. 2023. PMID: 37433993
-
Molecular and Immunohistochemical Alterations in Breast Cancer Patients in Upper Egypt.Rep Biochem Mol Biol. 2023 Jan;11(4):532-546. doi: 10.52547/rbmb.11.4.532. Rep Biochem Mol Biol. 2023. PMID: 37131903 Free PMC article.
-
Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients.Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2775-2786. doi: 10.1007/s00259-023-06232-1. Epub 2023 Apr 24. Eur J Nucl Med Mol Imaging. 2023. PMID: 37093312
-
Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer 99mTc-HP-Ark2: a pilot study.J Transl Med. 2023 Jan 11;21(1):19. doi: 10.1186/s12967-022-03865-y. J Transl Med. 2023. PMID: 36631812 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous